<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ketendo</journal-id><journal-title-group><journal-title xml:lang="ru">Клиническая и экспериментальная тиреоидология</journal-title><trans-title-group xml:lang="en"><trans-title>Clinical and experimental thyroidology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-5472</issn><issn pub-type="epub">2310-3787</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/ket2017245-56</article-id><article-id custom-type="elpub" pub-id-type="custom">ketendo-8748</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Studies</subject></subj-group></article-categories><title-group><article-title>Взаимосвязь гормональной и цитокиновой регуляции при аутоиммунном тиреоидите</article-title><trans-title-group xml:lang="en"><trans-title>Correlation of hormonal and cytokines regulation in case of autoimmune thyroiditis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1085-3632</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Здор</surname><given-names>Виктория Владимировна</given-names></name><name name-style="western" xml:lang="en"><surname>Zdor</surname><given-names>Victoria V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н.</p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">victoria.zdor@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>&lt;p&gt;ФГБОУ ВО &amp;ldquo;Тихоокеанский государственный медицинский университет&amp;rdquo;;&amp;nbsp;Клиника диабета и эндокринных заболеваний&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;Pasific State Medical University;&amp;nbsp;Clinic of diabetes and endocrine diseases&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>11</day><month>10</month><year>2017</year></pub-date><volume>13</volume><issue>2</issue><fpage>45</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Здор В.В., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Здор В.В.</copyright-holder><copyright-holder xml:lang="en">Zdor V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.cet-endojournals.ru/jour/article/view/8748">https://www.cet-endojournals.ru/jour/article/view/8748</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Исследование различных аспектов иммунопатогенеза аутоиммунного тиреоидита (АИТ), занимающего первое место среди аутоиммунной патологии человека, является актуальной проблемой современной медицины. Лечение аутоиммунного гипотиреоза сводится к заместительной терапии тиреоидными гормонами (ТГ), которые на сегодняшний день рассматриваются в качестве суперантигенов при аутоиммунном воспалении щитовидной железы (ЩЖ) и теоретически могут способствовать персистенции и прогрессированию воспалительного процесса. О взаимосвязи функциональной активности тиреоцитов и иммуноцитов через синтезируемые ими гормоны и цитокины, через рецепторы к тиреотропному гормону (ТТГ) на иммуноцитах и рецепторы к цитокинам на тиреоцитах, о возможной дисрегуляции этих взаимодействий при изменении уровней ТГ, ТТГ и/или цитокинов известно около 30 лет. Однако до сих пор не существует ясного представления о причинах нарушения этих взаимодействий, о первичном триггерном механизме АИТ, что существенным образом тормозит прогресс в лечении.</p></sec><sec><title>Цель</title><p>Цель. На основании комплексной оценки гормональных и иммунологических маркеров (ТТГ, ТГ и Treg, Th1-, Th2-, Th17-маркерных цитокинов) с исследованием возможных взаимосвязей их показателей у пациентов с различными клиническими вариантами течения АИТ исходно и на фоне заместительной терапии ТГ определить различия в функциональной активности различных типов иммунокомпетентных клеток в зависимости от тяжести воспалительного процесса для прогнозирования дальнейшего клинического течения АИТ, оптимизации протоколов терапии и своевременной коррекции стратегии лечения.</p></sec><sec><title>Методы</title><p>Методы. В проспективном исследовании у больных АИТ оценивали показатели сывороточного уровня оппозитных цитокинов и их рецепторов до начала терапии ТГ и на фоне лечения с помощью современных методов иммуноферментного анализа с иммунохемилюминесцентными и электрохемилюминесцентными способами детекции.</p></sec><sec><title>Результаты</title><p>Результаты. Выявлена избыточная продукция Th1-, Th2-, Th17- и Tregs маркерных цитокинов при дефиците TGF-β1, тесно ассоциированная с тяжестью аутоиммунного гипотиреоза. На фоне терапии ТГ показатели большинства цитокинов снижались или нормализовались, за исключением IL-6, IL-8, IL-2, IFN-g, TNF-α. Наибольшие отличия от нормы были зафиксированы при осложненном течении гипотиреоза.</p></sec><sec><title>Заключение</title><p>Заключение. Высокий сывороточный уровень TNF-α при АИТ является надежным маркером неблагоприятного течения и предиктором начала заместительной гормональной терапии при субклиническом течении. Показателями сохранности функционирующего тиреоидногоэпителия являются системные уровни IL-8 и IL-22, их динамическое снижение в сыворотке крови – прогностически неблагоприятный фактор, свидетельствующий о прогрессирующей потере функционально активной тиреоидной ткани и возможном нарастании гипофункции ЩЖ при АИТ. Многократно повышенные показатели IL-1α, IL-6 и IFN-γ могут рассматриваться в качестве предикторов тяжести клинического течения АИТ и аутоиммунного воспаления в ЩЖ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Studied immune aspects of the pathogenesis of autoimmune thyroiditis (AIT), which occupies the first place among human autoimmune pathologies. Treatment of the disease is based on thyroid hormones (TH) replacement therapy. TH are today considered to be super antigens in autoimmune inflammation of the thyroid gland.</p></sec><sec><title>Aims</title><p>Aims. On the basis of complex assessment of hormonal and immunological markers (TSH, TH, Treg, the Th1-, Th2-, Th17-marker cytokines) with a research of possible interrelations of their indicators at patients with various clinical options of a current of AIT initially and against the background of replacement therapy of TH to define differences in functional activity of various types of immunocompetent cages depending on weight of inflammatory process for forecasting of a further clinical current of AIT, optimization of protocols of therapy and timely correction of strategy of treatment.</p></sec><sec><title>Methods</title><p>Methods. In a prospective study, patients with AIT were evaluated for serum levels of cytokines and their receptors before initiating TH replacement therapy and on treatment by means of the ELISA modern methods with immuneсhemiluminescence and electroсhemiluminescence ways of detection.</p></sec><sec><title>Results</title><p>Results. Patients suffering from AIT showed an excess production of Th1-, Th2-, Th17- and Tregs marker cytokines with a deficiency of TGF-β1, closely connected with autoimmune hypothyroidism severity. Under pressure of TH therapy the indices of most cytokines decreased or improved, with the exception of IL-6, IL-8, IL-2, IFN-g, TNF-α. The greatest variations from the normal range were recorded in the complicated hypothyroidism.</p></sec><sec><title>Conclusions</title><p>Conclusions. High serum TNF-α level in the onset of the disease is an important marker for the unfavourable AIT course and a predictor of hormone replacement therapy in case of its subclinical course. Safety indexes of functional thyroid epithelium are systemic levels of IL-8 and IL-22, their dynamic reduction in blood serum is an adverse factor, indicating a progressive loss of functionally active thyroid tissue and a possible increase of hypothyroidism in case of subclinical AIT course. If specific gravity and magnitudes of IL-1α, IL-6 and IFN-γ exceed manifold they can be considered to be predictors of AIT clinical course severity and autoimmune inflammation in the thyroid.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>аутоиммунный тиреоидит</kwd><kwd>тиреоидные гормоны</kwd><kwd>цитокины</kwd></kwd-group><kwd-group xml:lang="en"><kwd>autoimmune thyroiditis</kwd><kwd>thyroid hormones</kwd><kwd>cytokines</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">ФГБОУ ВО ТГМУ Минздрава России</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Caturegli P, De Remigis A, Chuang K, et al. Hashimoto’s thyroiditis: celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records. Thyroid. 2013;23(2): 142-150. doi: 10.1089/thy.2012.0554.</mixed-citation><mixed-citation xml:lang="en">Caturegli P, De Remigis A, Chuang K, et al. Hashimoto’s thyroiditis: celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records. Thyroid. 2013;23(2): 142-150. doi: 10.1089/thy.2012.0554.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Болезни щитовидной железы / Под ред. Л.И. Браверманна. – М.: Медицина, 2000. [Braverman LE, editor. Diseases of the thyroid. Moscow: Medicine; 2000. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Болезни щитовидной железы / Под ред. Л.И. Браверманна. – М.: Медицина, 2000. [Braverman LE, editor. Diseases of the thyroid. Moscow: Medicine; 2000. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kristensen B. Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls. Dan Med J. 2016;63(2). pii: B5177.</mixed-citation><mixed-citation xml:lang="en">Kristensen B. Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls. Dan Med J. 2016;63(2). pii: B5177.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Pyzik A, Grywalska E, Matyjaszek-Matuszek B, Rolinski J. Immune disorders in Hashimoto’s thyroiditis: what do we know so far? J Immunol Res. 2015;2015:979167. doi: 10.1155/2015/979167.</mixed-citation><mixed-citation xml:lang="en">Pyzik A, Grywalska E, Matyjaszek-Matuszek B, Rolinski J. Immune disorders in Hashimoto’s thyroiditis: what do we know so far? J Immunol Res. 2015;2015:979167. doi: 10.1155/2015/979167.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ярилин А.А. Иммунология. – М.: ГЭОТАР-Медиа, 2010. – 752 с. [Yarilin AA. Immunology. Moscow: GEOTAR-Media; 2010. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Ярилин А.А. Иммунология. – М.: ГЭОТАР-Медиа, 2010. – 752 с. [Yarilin AA. Immunology. Moscow: GEOTAR-Media; 2010. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res. 2011;31(10):721-731. doi: 10.1089/jir.2011.0049.</mixed-citation><mixed-citation xml:lang="en">Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res. 2011;31(10):721-731. doi: 10.1089/jir.2011.0049.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Герасимов Г.А., и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению аутоиммунного тиреоидита у взрослых. – М.; 2013. [Dedov II, Mel’nichenko GA, Gerasimov GA, et al. Klinicheskierekomendatsii Rossiyskoy assotsiatsii endokrinologov po diagnostike i lecheniyu autoimmunnogo tireoidita u vzroslykh. Moscow; 2013. (In Russ.)] Доступно по ссылке: https://www.endocrincentr.ru/specialists/science/nauchnye-publikacii/konsensusy-i-klinicheskie-rekomendacii.</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Мельниченко Г.А., Герасимов Г.А., и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению аутоиммунного тиреоидита у взрослых. – М.; 2013. [Dedov II, Mel’nichenko GA, Gerasimov GA, et al. Klinicheskierekomendatsii Rossiyskoy assotsiatsii endokrinologov po diagnostike i lecheniyu autoimmunnogo tireoidita u vzroslykh. Moscow; 2013. (In Russ.)] Доступно по ссылке: https://www.endocrincentr.ru/specialists/science/nauchnye-publikacii/konsensusy-i-klinicheskie-rekomendacii.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shimon I, Pariente C, Shlomo-David J, et al. Transient elevation of triiodothyronine caused by triiodothyronine autoantibody associated with acute Epstein-Barr-virus infection. Thyroid. 2003;13(2):211-215. doi: 10.1089/105072503321319530.</mixed-citation><mixed-citation xml:lang="en">Shimon I, Pariente C, Shlomo-David J, et al. Transient elevation of triiodothyronine caused by triiodothyronine autoantibody associated with acute Epstein-Barr-virus infection. Thyroid. 2003;13(2):211-215. doi: 10.1089/105072503321319530.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Beato-Vibora PI, Alejo-Gonzalez S. Avoiding misdiagnosis due to antibody interference with serum free thyroxin. Int J Endocrinol Metab. 2017;15(1):e37792. doi: 10.5812/ijem.37792.</mixed-citation><mixed-citation xml:lang="en">Beato-Vibora PI, Alejo-Gonzalez S. Avoiding misdiagnosis due to antibody interference with serum free thyroxin. Int J Endocrinol Metab. 2017;15(1):e37792. doi: 10.5812/ijem.37792.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Takano K, Yamamoto M, Takahashi H, Himi T. Recent advances in knowledge regarding the head and neck manifestations of IgG4-related disease. Auris Nasus Larynx. 2017;44(1):7-17. doi: 10.1016/j.anl.2016.10.011.</mixed-citation><mixed-citation xml:lang="en">Takano K, Yamamoto M, Takahashi H, Himi T. Recent advances in knowledge regarding the head and neck manifestations of IgG4-related disease. Auris Nasus Larynx. 2017;44(1):7-17. doi: 10.1016/j.anl.2016.10.011.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kristensen B, Hegedus L, Madsen HO, et al. Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto’s thyroiditis. Clin Exp Immunol. 2015;180(1):58-69. doi: 10.1111/cei.12557.</mixed-citation><mixed-citation xml:lang="en">Kristensen B, Hegedus L, Madsen HO, et al. Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto’s thyroiditis. Clin Exp Immunol. 2015;180(1):58-69. doi: 10.1111/cei.12557.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Alnaqdy A, Al-Maskari M. Levels of cytokines and thyroid autoantibodies in Omani patients with Graves’ disease. Br J Biomed Sci. 2007;64(4):164-167.</mixed-citation><mixed-citation xml:lang="en">Alnaqdy A, Al-Maskari M. Levels of cytokines and thyroid autoantibodies in Omani patients with Graves’ disease. Br J Biomed Sci. 2007;64(4):164-167.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rasmussen AK, Bendtzen K, Feldt-Rasmussen U. Thyrocyte-interleukin-1 interactions. Exp Clin Endocrinol Diabetes. 2000; 108(2):67-71. doi: 10.1055/s-2000-5797.</mixed-citation><mixed-citation xml:lang="en">Rasmussen AK, Bendtzen K, Feldt-Rasmussen U. Thyrocyte-interleukin-1 interactions. Exp Clin Endocrinol Diabetes. 2000; 108(2):67-71. doi: 10.1055/s-2000-5797.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rapoport B, McLachlan SM. Graves’ hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J Clin Endocrinol Metab. 2014;99(11):4060-4061. doi: 10.1210/jc.2014-3011.</mixed-citation><mixed-citation xml:lang="en">Rapoport B, McLachlan SM. Graves’ hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J Clin Endocrinol Metab. 2014;99(11):4060-4061. doi: 10.1210/jc.2014-3011.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Козлов В.А. Клетки-супрессоры – основа иммунопатогенеза аутоиммунных заболеваний. // Медицинская иммунология. – 2016. – Т.18. – №1. – С. 7–14. [Kozlov VA. Suppressor cells – the basis of immunopathogenesis autoimmune diseases. Medical Immunology (Russia).2016;18(1):7-14. (In Russ.)]. doi: 10.15789/1563-0625-2016-1-7-14.</mixed-citation><mixed-citation xml:lang="en">Козлов В.А. Клетки-супрессоры – основа иммунопатогенеза аутоиммунных заболеваний. // Медицинская иммунология. – 2016. – Т.18. – №1. – С. 7–14. [Kozlov VA. Suppressor cells – the basis of immunopathogenesis autoimmune diseases. Medical Immunology (Russia).2016;18(1):7-14. (In Russ.)]. doi: 10.15789/1563-0625-2016-1-7-14.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Topliss DJ. Clinical update in aspects of the management of autoimmune thyroid diseases. Endocrinol Metab (Seoul). 2016;31(4): 493-499. doi: 10.3803/EnM.2016.31.4.493.</mixed-citation><mixed-citation xml:lang="en">Topliss DJ. Clinical update in aspects of the management of autoimmune thyroid diseases. Endocrinol Metab (Seoul). 2016;31(4): 493-499. doi: 10.3803/EnM.2016.31.4.493.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013; 2(4):215-228. doi: 10.1159/000356507.</mixed-citation><mixed-citation xml:lang="en">Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013; 2(4):215-228. doi: 10.1159/000356507.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bai X, Sun J, Wang W, et al. Increased differentiation of Th22 cells in Hashimoto’s thyroiditis. Endocr J. 2014;61(12):1181-1190. doi: 10.1507/endocrj.EJ14-0265.</mixed-citation><mixed-citation xml:lang="en">Bai X, Sun J, Wang W, et al. Increased differentiation of Th22 cells in Hashimoto’s thyroiditis. Endocr J. 2014;61(12):1181-1190. doi: 10.1507/endocrj.EJ14-0265.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zielinski CE, Mele F, Aschenbrenner D, et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature. 2012;484(7395):514-518. doi: 10.1038/nature10957.</mixed-citation><mixed-citation xml:lang="en">Zielinski CE, Mele F, Aschenbrenner D, et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature. 2012;484(7395):514-518. doi: 10.1038/nature10957.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Csaba G, Pallinger E. Thyrotropic hormone (TSH) regulation of triiodothyronine (T(3)) concentration in immune cells. Inflamm Res. 2009;58(3):151-154. doi: 10.1007/s00011-008-8076-8.</mixed-citation><mixed-citation xml:lang="en">Csaba G, Pallinger E. Thyrotropic hormone (TSH) regulation of triiodothyronine (T(3)) concentration in immune cells. Inflamm Res. 2009;58(3):151-154. doi: 10.1007/s00011-008-8076-8.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol. 2011;22(5):385-390. doi: 10.1097/ICU.0b013e3283499446.</mixed-citation><mixed-citation xml:lang="en">Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol. 2011;22(5):385-390. doi: 10.1097/ICU.0b013e3283499446.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med. 2016;22(3):230-241. doi: 10.1016/j.molmed.2016.01.001.</mixed-citation><mixed-citation xml:lang="en">Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med. 2016;22(3):230-241. doi: 10.1016/j.molmed.2016.01.001.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao C, Gao Y, Zhao L, et al. The expression and function of the neonatal Fc receptor in thyrocytes of Hashimoto’s thyroiditis. Int Immunopharmacol. 2017;44:53-60. doi: 10.1016/j.intimp.2016.12.032.</mixed-citation><mixed-citation xml:lang="en">Zhao C, Gao Y, Zhao L, et al. The expression and function of the neonatal Fc receptor in thyrocytes of Hashimoto’s thyroiditis. Int Immunopharmacol. 2017;44:53-60. doi: 10.1016/j.intimp.2016.12.032.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
